Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Highlights
The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial has previously established that semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events (MACE) by 20%. This new exploratory analysis expands those findings, focusing on the broader impact on healthcare utilization.
Key findings from the analysis include:
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.